Template:Main Page News: Difference between revisions
From Embryology
mNo edit summary |
mNo edit summary |
||
Line 7: | Line 7: | ||
PMID 27294876 | [http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4128.html Nat Med.] | PMID 27294876 | [http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4128.html Nat Med.] | ||
Thalidomide (and derivatives lenalidomide and pomalidomide) are treatments for hematologic malignancies, multiple myeloma (MM) and del(5q) myelodysplastic syndrome (MDS). Cereblon (CRBN) is the primary target for both the anticancer and teratogenic effects, and it promotes the maturation of CD147 ([[Abnormal Development - Thalidomide#CD147 (Basigin)|also known as Basigin]]) a member of the immunoglobulin superfamily). | Thalidomide (and derivatives lenalidomide and pomalidomide) are treatments for hematologic malignancies, [http://www.omim.org/entry/254500 multiple myeloma] (MM) and del(5q) [http://www.omim.org/entry/614286 myelodysplastic syndrome] (MDS). Cereblon (CRBN) is the primary target for both the anticancer and teratogenic effects, and it promotes the maturation of CD147 ([[Abnormal Development - Thalidomide#CD147 (Basigin)|also known as Basigin]]) a member of the immunoglobulin superfamily). | ||
Zebrafish knockdown of CD147 was shown to match the teratogenic effects of thalidomide exposure. | Zebrafish knockdown of CD147 was shown to match the teratogenic effects of thalidomide exposure. |
Revision as of 14:40, 17 June 2016
News - Thalidomide Molecular Mechanism shown in Zebrafish |
PMID 27294876 | Nat Med. Thalidomide (and derivatives lenalidomide and pomalidomide) are treatments for hematologic malignancies, multiple myeloma (MM) and del(5q) myelodysplastic syndrome (MDS). Cereblon (CRBN) is the primary target for both the anticancer and teratogenic effects, and it promotes the maturation of CD147 (also known as Basigin) a member of the immunoglobulin superfamily). Zebrafish knockdown of CD147 was shown to match the teratogenic effects of thalidomide exposure. |
|